Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04657822 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04657822 · ClinicalTrials.gov record · last posted 2026-06-08

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Name: Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — clinical trial record (NCT04657822)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorNovartis Pharmaceuticals

Started2021-06-10

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Amendment record 39 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 39 times since 2020-12-01; most recent amendment 2026-06-04. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2021-06-15

Status change Not Yet Recruiting→Recruitingv2

Trial Details

NCT Number	NCT04657822
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Sickle Cell Disease
Enrollment	130 participants
Start Date	2021-06-10
Primary Completion	2031-06-10 (estimated)
Study Completion	2031-06-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-08